» Articles » PMID: 27322113

The Delineation of Intraprostatic Boost Regions for Radiotherapy Using Multimodality Imaging

Overview
Journal Future Oncol
Specialty Oncology
Date 2016 Jun 21
PMID 27322113
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Dose escalation to the prostate improves tumor control but at the expense of increased rectal toxicity. Modern imaging can be used to detect the most common site of recurrence, the intraprostatic lesion (IPL), which has led to the concept of focusing dose escalation to the IPL in order to improve the therapeutic ratio. Imaging must be able to detect lesions with adequate sensitivity and specificity to accurately delineate the IPL. This information must be carefully integrated into the radiotherapy planning process to ensure the dose is targeted to the IPL. This review will consider the role and challenges of multiparametric MRI and PET computed tomography in delineating a tumor boost to be delivered by external beam radiotherapy.

Citing Articles

The Dose Difference of Dominant Intraprostatic Lesions (DILs) Defined by Magnetic Resonance-Guided and arc-based Intensity Modulated Radiation Therapy (IMRT), and the Association between Dose Difference and Recurrent Prostate Cancer.

Amantakul A, Kanthawang T, Tantraworasin A, Tharavichitkul E Asian Pac J Cancer Prev. 2024; 25(9):3269-3275.

PMID: 39342606 PMC: 11700308. DOI: 10.31557/APJCP.2024.25.9.3269.


MRI-guided adaptive radiotherapy for prostate cancer: When do we need to account for intra-fraction motion?.

Lawes R, Barnes H, Herbert T, Mitchell A, Nill S, Oelfke U Clin Transl Radiat Oncol. 2022; 37:85-88.

PMID: 36118123 PMC: 9471961. DOI: 10.1016/j.ctro.2022.09.001.


Evaluation of Dose-Painting in the Dominant Intraprostatic Lesions by Radiobiological Parameters using Ga- PSMA PET/CT.

Bamneshin K, Mahdavi S, Bitarafan-Rajabi A, Geramifar P, Hejazi P, Koosha F J Biomed Phys Eng. 2022; 12(4):369-376.

PMID: 36059285 PMC: 9395631. DOI: 10.31661/jbpe.v0i0.1912-1006.


MR-guided radiotherapy for prostate cancer: state of the art and future perspectives.

Sritharan K, Tree A Br J Radiol. 2022; 95(1131):20210800.

PMID: 35073158 PMC: 8978250. DOI: 10.1259/bjr.20210800.


Trimodality PET/CT/MRI and Radiotherapy: A Mini-Review.

Decazes P, Hinault P, Veresezan O, Thureau S, Gouel P, Vera P Front Oncol. 2021; 10:614008.

PMID: 33614497 PMC: 7890017. DOI: 10.3389/fonc.2020.614008.